Diabetic Macular Oedema Clinical Trial
Official title:
Pilot Study of Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema
This pilot study aims to establish that treatment with near infrared light (NIR) reduces diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive beneficial effect at retinal cellular level.
This pilot study aims to establish that treatment with near infrared light (NIR) reduces
diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive
beneficial effect at retinal cellular level.
Diabetic retinopathy is a common cause of severe loss of vision and the most common cause of
blindness in individuals between the ages of 20 and 65 years in developed countries.Swelling
of the central retina or "macular oedema". Patients will be treated in an office clinic,three
times a week for a treatment duration of 2 minutes per session, a total of 12 times over the
duration of 4 weeks and will be assessed at 8 weeks to establish any change induced in
retinal oedema. Safety follow up will be assessed at 3 and 6 months post treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04576689 -
Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy
|
Phase 2 | |
| Completed |
NCT02554747 -
Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa
|
N/A | |
| Withdrawn |
NCT02309476 -
Sub-threshold Photocoagulation of Diabetic Macular Oedema
|
N/A | |
| Terminated |
NCT02207712 -
Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
|
N/A | |
| Completed |
NCT02457884 -
Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema
|
N/A | |
| Completed |
NCT00148330 -
Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study
|
Phase 2/Phase 3 | |
| Completed |
NCT03495765 -
To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT00167518 -
Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)
|
Phase 2/Phase 3 | |
| Completed |
NCT01787669 -
Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
|
Phase 2 | |
| Completed |
NCT01175070 -
Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
|
Phase 4 | |
| Terminated |
NCT00427986 -
Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema
|
N/A | |
| Completed |
NCT00333671 -
Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema)
|
N/A | |
| Completed |
NCT02731911 -
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
|
||
| Completed |
NCT00148265 -
A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema
|
Phase 2/Phase 3 |